ADC Therapeutics SA (NYSE:ADCT)
$ 1.295 +0.035 (+2.78%) Market Cap: 164.71 Mil Enterprise Value: 50.37 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 41/100

Q1 2026 ADC Therapeutics SA Earnings Call Transcript

May 04, 2026 / 12:30PM GMT
Release Date Price: $3.68 (-3.92%)
Operator

Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Q1 2026 earnings conference call. (Operator Instructions) This call is being recorded on Monday, May 4, 2026. I would now like to turn the conference over to Nicole Riley, Head of Investor Relations and Corporate Communications. Please go ahead.

Nicole Riley
ADC Therapeutics SA - Investor Relations

Thank you, operator. Today, we issued a press release announcing our first quarter 2026 financial results and business updates. This release and the slides we will use in today's presentation are available on the Investors Section of the ADC Therapeutics website. I'm joined on today's call by our Chief Executive Officer, Ameet Mallik, who will discuss our operational performance and recent business highlights, followed by our Chief Financial Officer, Pepe Carmona, who will review our first quarter 2026 financial results. We will then open the call to questions.

Before we begin, I would like to remind listeners that some of the statements made during this conference call will contain

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot